IBSRELA
Drug
Ardelyx, Inc.
Total Payments
$3.7M
Transactions
75,191
Doctors
20,418
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.3M | 41,312 | 16,399 |
| 2023 | $846,258 | 24,723 | 8,857 |
| 2022 | $590,057 | 9,156 | 3,808 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1.6M | 74,345 | 44.1% |
| Consulting Fee | $921,655 | 531 | 24.7% |
| Unspecified | $836,625 | 202 | 22.4% |
| Education | $215,000 | 9 | 5.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $61,447 | 7 | 1.6% |
| Travel and Lodging | $36,807 | 85 | 1.0% |
| Grant | $14,500 | 12 | 0.4% |
Payments by Type
General
$2.9M
74,989 transactions
Research
$836,625
202 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS | Ardelyx, Inc. | $550,626 | 1 |
| AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | Ardelyx, Inc. | $206,668 | 0 |
| Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old | Ardelyx, Inc. | $79,332 | 0 |
Top Doctors Receiving Payments for IBSRELA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Ann Arbor, MI | $1,969 | 12 |
| , DO | Gastroenterology | Mesa, AZ | $1,961 | 15 |
| , MD | Internal Medicine | Houston, TX | $1,911 | 22 |
| , M.D | Gastroenterology | Coral Springs, FL | $1,909 | 23 |
| , MD | Internal Medicine | Forest Hills, NY | $1,882 | 32 |
| , M.D | Gastroenterology | Rochester, MN | $1,875 | 1 |
| , M.D | Gastroenterology | Olathe, KS | $1,870 | 12 |
| , M.D | Gastroenterology | Lancaster, CA | $1,839 | 35 |
| , M.D | Gastroenterology | Cranston, RI | $1,832 | 40 |
| , APN | Adult Health | Hoffman Estates, IL | $1,809 | 10 |
| , MD | Gastroenterology | Indiana, PA | $1,806 | 17 |
| , MD | Gastroenterology | Marietta, GA | $1,806 | 9 |
| , M.D | Gastroenterology | Gurnee, IL | $1,800 | 20 |
| , DO | Gastroenterology | Mesa, AZ | $1,718 | 10 |
| , MD | Gastroenterology | Stanford, CA | $1,715 | 4 |
| , M.D., M.P.H | Gastroenterology | Miami, FL | $1,694 | 33 |
| , MD | Gastroenterology | Marietta, GA | $1,681 | 10 |
| , M.D | Gastroenterology | Arlington, VA | $1,663 | 12 |
| , M.D | Gastroenterology | Southlake, TX | $1,661 | 3 |
| , MD | Gastroenterology | Anaheim, CA | $1,656 | 21 |
| , MD | Gastroenterology | Easton, PA | $1,650 | 2 |
| , M.D | Internal Medicine | Southlake, TX | $1,643 | 2 |
| , MD | Gastroenterology | Centralia, IL | $1,640 | 12 |
| , MD | Gastroenterology | Saint Louis, MO | $1,638 | 2 |
| , M.D | Gastroenterology | Annapolis, MD | $1,628 | 8 |
Ad
Manufacturing Companies
- Ardelyx, Inc. $3.7M
Product Information
- Type Drug
- Total Payments $3.7M
- Total Doctors 20,418
- Transactions 75,191
About IBSRELA
IBSRELA is a drug associated with $3.7M in payments to 20,418 healthcare providers, recorded across 75,191 transactions in the CMS Open Payments database. The primary manufacturer is Ardelyx, Inc..
Payment data is available from 2022 to 2024. In 2024, $2.3M was paid across 41,312 transactions to 16,399 doctors.
The most common payment nature for IBSRELA is "Food and Beverage" ($1.6M, 44.1% of total).
IBSRELA is associated with 3 research studies, including "TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS" ($550,626).